Growth retardation is a major complication of the use of long-term steroid therapy in children [1] . Daily steroid therapy has profound effects on growth; alternate day therapy has less 12]. The mechanisms by which steroids inhibit growth are many. The review of how glucocorticoids may inhibit cell proliferation and growth points out the many cell mechanisms vulnerable to steroid effect: depression of cell energy metabolism and direct effects on cell receptor sites that modify either RNA or protein synthesis [3-5] (see Baxter, this issue).
Animal models also have been useful in investigating steroid effects on growth. Following shortterm administration that inhibits growth. catch-up growth occurs similar to that seen in recovery from malnutrition [6] . Accelerated growth includes specific organ systems as well as whole body. Catch-up growth on stopping steroid therapy is not invariable. Large doses given over long periods can result in irreversible growth retardation which is more easily induced at less mature stages of development either in children or in experimental animals [3] .
Children with kidney disease who are likely to be given growth suppressive doses of steroids fall into two general groups-those with the nephrotic syndrome or some type of glomerulonephritis, and those who have received a renal transplant. In this report, we present some clinical observations of a child with nephrosis who was treated long-term with prednisone and became irreverisbly growth-retarded. From this example, certain points emerge that illustrate some common problems in using steroid therapy for children with the nephrotic syndrome or other glomerulopathies. We also review growth performance of children after renal transplant, and we discuss, from a clinical perspective, how steroid therapy may affect growth.
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Steroid suppression of growth in children with the nephrotic syndrome Alternate-day steroid therapy generally is thought to have little effect on growth when it is used in treatment of the nephrotic syndrome. While metabolic and nutritional consequences of nephrosis may interfere with growth, the usual steroid-dependent case is not likely to have proteinuria and edema sufficient to affect growth and is a relatively good model for examining growth-suppressing effects of steroids in children. The following case is illustrative.
Case report
The patient had shown normal growth and development until the age of 2.6 yr, when he developed the nephrotic syndrome ( Fig. IA) . The initial clinical picture was not associated with hematuria, hypertension, or azotemia. A percutaneous renal biopsy demonstrated "minimal change disease" ("nil" lesion).
Daily prednisone therapy (60 mg/m2/day) resulted in prompt diuresis and clearing of the proteinuria within 3 weeks. Daily therapy was given for a total of 4 weeks, then was changed to 40 mg/m2/ day given in divided dosages on 3 consecutive days of each week. Two weeks after beginning this maintenance therapy, he had an exacerbation of his nephrotic syndrome, necessitating reinstitution of daily prednisone therapy. Remission was induced within 10 days, and maintenance therapy was once again started, but another exacerbation occurred after 5 weeks. From 2.6 until 5.7 yr ( Fig. 1, A-B ), the patient experienced multiple recurrences of his disease, and, except for one 12-week period, he was constantly receiving steroid therapy in various doses and schedules of administration. Stature for age fell from the 50th, to below the 3rd percentile for age; weight, by contrast, increased to the 95th percentile for age.
At 5.7 yr ( Fig. 1, point B ). despite this course, the patient had normal renal function. He was given cyclophosphamide for 12 weeks (2.1 mg/kg/day), and steroids were discontinued. From then until 7.8 yr of age-a period of 2.1 years (108 weeks)-he did not have a recurrence and received no therapy ( Fig. 1 , B-C).
Growth rate increased, and some catch-up growth occurred.
Stature for age, however, stabilized in the 10th percentile rather 0085-2538/78/00 14-0365$0 1 .00 than the level before illness of 50th percentile for age. An exacerbation of the nephrotic syndrome occurred at 7.8 yr, which responded to daily steroid administration. A frequently relapsing course returned and has continued despite constant alternate morning steroid administration and intermittent courses of daily steroids. Once again, growth rate decreased ( Fig. 1 , C-D).
This example demonstrates several points of importance concerning steroid administration in children with kidney disease. Significant growth inhibition occurred, even in the absence of deteriorating renal function and in spite of attempts to limit the amount of daily therapy. During the 2.9 yr (150 weeks) between onset of nephrosis and institution of cyclophosphamide ( Fig. 1) , the patient received daily therapy for only 30 weeks while receiving intermittent therapy (3 day/week, divided dose, or a!ternate morning single dose) for 108 weeks, and no therapy for 12 weeks. Despite the fact that he was not in ill health during most of this time and undernutrition was obviously not a problem, he only gained 12 or 23 cm, or 54%, needed to achieve normal stature for his age.
It is not surprising that growth retardation occurred during the periods the child received daily therapy in doses given. Early studies jjl-2j have demonstrated that daily steroid therapy, in doses appreciably less than his, were associated with growth retardation [11. The poor growth the child experienced when he received alternate day therapy is less rapidly explained in view of the normal growth reported in children with asthma given alternate-day therapy 230 [2] . Alternate-day therapy in experimental animal -220 models also had no growth inhibiting effects [7] . Chesney et al [8] , however, recently reported re-.' suIts of alternate-day therapy (2.5 mg/kg) in 25 chil-180 ' dren with renal disease who did not have impaired function (GFR). Of these 25 children 18 had de--iso ' creased growth rates; this finding was associated 140 with poor bone mineralization.
Low concentrations of glucocorticoids are suf--ito ficient to suppress growth hormone levels and possible somatomedin action [4, 5] . Small changes in -80 metabolic clearance of prednisone may occur in the -70 nephrotic syndrome that prolong the glucocorticoid effect. This and slightly different dose schedules -40 may account for the growth retardation seen in these children in contrast to what is seen in those with asthma. It is also possible that proteinuria or edema, or both may affect growth although moderate proteinuria usually has little physiological effect and gross edema is uncommon in children who respond to treatment. Although alternate-day therapy had no effect in the experimental model reported [71, there is difficulty in assuming that the dose schedule used can be equated to that given children with kidney disease.
The patient did exhibit catch-up growth when he no longer received steroids. Growth of 15 cm is greater than the 13 that is normal for his age for that period. It is, however, less than the 23 cm the child needed to return to the normal stature percentile for age. This is consistent with earlier experience and reflects both the immature age of the child at time of treatment and the intensity and duration of treatme nt.
In summary, children with nephrosis or glomerular disease who receive alternate-day steroid therapy are at risk to growth retardation which may be permanent. The poor growth is associated with poor bone mineralization.
Steroid therapy after renal transplantation
The factors affecting growth in children after transplant include the use of either daily or alternate-day steroid therapy, the child's growth potential at the time of transplantation [9] , and the adequacy of function of the transplanted kidney [101. Growth potential is predicted from a child's stature percentiles for both chronological age and bone age [11] .
Results in growth after transplant have varied. Potter et al [12] reported that children who receive less than 8.5 mg of prednisone/m2/day grow better than those who receive a higher dose. Saenger et a! [10] noted better growth in children who receive less than 6.5 mg/m2/day. Lilly et al [131 and De-Shazo et al [141 reported normal growth for age in 50% and 87% of children, respectively, who were treated with daily prednisone. Pennisi et al [15] noted that only 13% of their long-term transplant recipients grew more than 80% of expected height for age. These latter authors surmised that the difference in growth between their patients and those studied previously could be explained by differences in steroid dose around 1 yr after transplant: approximately 0.2 to 0.3 mg/kg/day in those with better growth [13, 14] in contrast to 0.56 mg/kg/day with poorer growth [15] .
Growth appears to be better when prednisone is given as a single dose on alternate days than when it is given in divided doses daily. Between 30 and 100% of children using this regimen grew at normal rates for age [16] [17] [18] [19] .
No controlled studies have been reported comparing growth performance and renal function in children treated either with daily or alternate day therapy.
Mechanisms of steroid inhibition of growth in children
Studies in children that focus on mechanisms of steroid inhibition of growth are few. The influence of steroids on cell metabolism point to many theoretical possibilities (see Baxter, this issue). The finding of an association between bone mineralization and poor growth raises some other possibilities as to how steroids might inhibit growth.
Steroid therapy depresses calcium absorption [20] , decreases serum concentrations of 25-hydroxyvitamin D [20] , and increases secretion of parathyroid hormone [21] . Each of these effects may affect bone mineralization, which may affect growth.
Phosphate depletion may also occur with steroid therapy, particularly when given to a child after renal transplantation. Children with hypophosphatemic rickets improve growth when phosphate is given [22] . Hypophosphatemia may occur after transplant, and a number of factors may contribute to its development. Substituting a functioning for a nonfunctioning kidney in a person with secondary hyperparathyroidism results in a phosphate diuresis [23] . Glucocorticoids increase renal phosphate ex-cretion [24] , probably by stimulating parathormone secretion and decreasing tubular reabsorption of phosphate [21] . Whatever the mechanisms, the phosphaturia common in children after transplant [25] may contribute to growth retardation. This effect, however, is likely to be short-lived, whereas growth-inhibiting effects prevail for long periods.
In summary, steroid therapy, including alternateday steroid therapy, has the capacity to inhibit growth and cause bone dernineralization in children with kidney disease-especially those with steroiddependent nephrotic syndrome and those who have undergone renal transplantation. The effect is less on alternate-day therapy. There is evidence that steroid effects upon phosphorus and calcium may contribute to bone demineralization and to growth inhibition. Glucocorticoids, however, may inhibit growth in any of several ways, including direct action on cell growth. The rate-limiting step for growth of children most readily inhibited by steroid therapy is not known. When identified, a key will be available for pacing therapy to avoid growth retardation. For the present, the minimum therapy necessary to achieve the desired clinical result still seems capable of inhibiting growth.
Summary
Glucorticoid therapy inhibits statural growth. Alternate-day therapy causes less growth suppression than does daily therapy, and, in experimental animals and children with asthma, it has been associated with normal growth. Although catch-up growth may occur after cessation of steroid therapy, this is not always the case, especially when therapy has been prolonged. In children treated with steroids for glomerulonephritis or nephrotic syndrome and especially in children after renal transplantation, factors other than steroid therapy may contribute to growth retardation. Steroids may suppress growth by direct action on cell metabolism, by inhibition of growth hormone or somatomedin and/or by effects on calcium and phosphorus metabolism. Present knowledge of mechanisms of action and dose-response relationships is incomplete, and it is difficult to prescribe therapy which will achieve a predictable therapeutic effect without inhibiting growth.
